Mutational profile of KRAS, NRAS, BRAF, PIK3CA, and AKT1 genes in colorectal cancer patients in a tertiary care hospital, Dhaka

Sharmin Chowdhury , Sheikh Joly Ferdous Ara , Shirazum Monira Mili , Tahani Momotaz , Md Maruf Ahmed Molla , Shaheda Anwar , Ahmed Abu Saleh
{"title":"Mutational profile of KRAS, NRAS, BRAF, PIK3CA, and AKT1 genes in colorectal cancer patients in a tertiary care hospital, Dhaka","authors":"Sharmin Chowdhury ,&nbsp;Sheikh Joly Ferdous Ara ,&nbsp;Shirazum Monira Mili ,&nbsp;Tahani Momotaz ,&nbsp;Md Maruf Ahmed Molla ,&nbsp;Shaheda Anwar ,&nbsp;Ahmed Abu Saleh","doi":"10.1016/j.adcanc.2022.100054","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Colorectal carcinoma (CRC) is the third most common cancer in the world and incidences are on the rise in Bangladesh. <em>KRAS, NRAS, BRAF, PIK3CA</em>, and <em>AKTI</em> gene mutations are predictive markers of biological therapies, monoclonal antibodies targeting EGFR. The purpose of this study was to detect <em>KRAS, NRAS, BRAF, PIK3CA</em>, and <em>AKT1</em> genes mutation in CRC patients by multiplex real-time Polymerase Chain Reaction (PCR) and evaluate the association of the mutations with clinicopathological features.</p></div><div><h3>Methodology</h3><p>This cross-sectional study was carried out in the Department of Microbiology &amp; Immunology, Bangabandhu Sheikh Mujib Medical University (BSMMU) from March 2019 to January 2020. Tissues from surgically resected colorectal tumors were collected from 44 histopathologically confirmed adult colorectal cancer patients, who were admitted in the Department of Colorectal Surgery, BSMMU.</p></div><div><h3>Results</h3><p>Among 44 histopathologically diagnosed colorectal cancer patients, <em>KRAS, BRAF</em>, and <em>PIK3CA</em> gene mutations were identified in 31.5%, 4.85%, and 4.85% tumors, respectively. In this study, no mutation was detected in <em>NRAS</em> and <em>AKT1</em> genes. Concurrent mutation in <em>KRAS</em> and <em>PIK3CA</em> genes were found in one patient. Among the 14 <em>KRAS</em> mutant cases, most (92.85%) were in exon 2 (codon 12/13) and only 7.15% of the mutations were in exon 3 (codon 61). No mutation was detected in codon 59, 117, and 146. Among the two <em>PIK3CA</em> mutations, one was present in exon 9 and another was in exon 20. <em>KRAS</em> mutations were significantly associated with well and moderately differentiated tumors than poorly differentiated tumors (p &lt; 0.05). Histopathologically there was no significant association of <em>KRAS</em> mutations with age, sex, tumor location, TNM staging, and other parameters.</p></div><div><h3>Conclusion</h3><p>A combined evaluation of genetic biomarkers can classify about one-third of colorectal cancer patients as mutant for any one of these <em>KRAS, BRAF</em>, and <em>PIK3CA</em> genes.</p></div>","PeriodicalId":72083,"journal":{"name":"Advances in cancer biology - metastasis","volume":"5 ","pages":"Article 100054"},"PeriodicalIF":2.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667394022000284/pdfft?md5=b86cf9836a1cb43a421bff404a03877e&pid=1-s2.0-S2667394022000284-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in cancer biology - metastasis","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667394022000284","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Colorectal carcinoma (CRC) is the third most common cancer in the world and incidences are on the rise in Bangladesh. KRAS, NRAS, BRAF, PIK3CA, and AKTI gene mutations are predictive markers of biological therapies, monoclonal antibodies targeting EGFR. The purpose of this study was to detect KRAS, NRAS, BRAF, PIK3CA, and AKT1 genes mutation in CRC patients by multiplex real-time Polymerase Chain Reaction (PCR) and evaluate the association of the mutations with clinicopathological features.

Methodology

This cross-sectional study was carried out in the Department of Microbiology & Immunology, Bangabandhu Sheikh Mujib Medical University (BSMMU) from March 2019 to January 2020. Tissues from surgically resected colorectal tumors were collected from 44 histopathologically confirmed adult colorectal cancer patients, who were admitted in the Department of Colorectal Surgery, BSMMU.

Results

Among 44 histopathologically diagnosed colorectal cancer patients, KRAS, BRAF, and PIK3CA gene mutations were identified in 31.5%, 4.85%, and 4.85% tumors, respectively. In this study, no mutation was detected in NRAS and AKT1 genes. Concurrent mutation in KRAS and PIK3CA genes were found in one patient. Among the 14 KRAS mutant cases, most (92.85%) were in exon 2 (codon 12/13) and only 7.15% of the mutations were in exon 3 (codon 61). No mutation was detected in codon 59, 117, and 146. Among the two PIK3CA mutations, one was present in exon 9 and another was in exon 20. KRAS mutations were significantly associated with well and moderately differentiated tumors than poorly differentiated tumors (p < 0.05). Histopathologically there was no significant association of KRAS mutations with age, sex, tumor location, TNM staging, and other parameters.

Conclusion

A combined evaluation of genetic biomarkers can classify about one-third of colorectal cancer patients as mutant for any one of these KRAS, BRAF, and PIK3CA genes.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
达卡某三级医院结直肠癌患者的KRAS、NRAS、BRAF、PIK3CA和AKT1基因突变谱
结直肠癌(CRC)是世界上第三大常见癌症,孟加拉国的发病率呈上升趋势。KRAS、NRAS、BRAF、PIK3CA和AKTI基因突变是靶向EGFR的生物疗法和单克隆抗体的预测标志物。本研究的目的是通过多重实时聚合酶链反应(PCR)检测结直肠癌患者的KRAS、NRAS、BRAF、PIK3CA和AKT1基因突变,并评估这些突变与临床病理特征的相关性。方法本横断面研究在微生物学系进行;Bangabandhu Sheikh Mujib医科大学(BSMMU)免疫学专业,2019年3月至2020年1月。收集44例经组织病理学证实的成年结直肠癌患者手术切除的结直肠肿瘤组织,这些患者均在BSMMU结直肠外科住院。结果在44例组织病理学诊断的结直肠癌患者中,KRAS、BRAF和PIK3CA基因突变的发生率分别为31.5%、4.85%和4.85%。本研究未检测到NRAS和AKT1基因突变。1例患者发现KRAS和PIK3CA基因同时突变。14例KRAS突变中,外显子2(密码子12/13)突变最多(92.85%),外显子3(密码子61)突变仅占7.15%。密码子59、117和146未检测到突变。在两个PIK3CA突变中,一个存在于外显子9,另一个存在于外显子20。与低分化肿瘤相比,KRAS突变与高分化和中度分化肿瘤显著相关(p <0.05)。组织病理学上,KRAS突变与年龄、性别、肿瘤位置、TNM分期和其他参数无显著相关性。结论综合评价遗传生物标志物可将约三分之一的结直肠癌患者分类为KRAS、BRAF和PIK3CA基因中的任意一种突变。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Advances in cancer biology - metastasis
Advances in cancer biology - metastasis Cancer Research, Oncology
CiteScore
2.40
自引率
0.00%
发文量
0
审稿时长
103 days
期刊最新文献
The effect of pDNA-Buforin II on the expression changes of lncRNAs PCA3, PCAT1, PRNCR1, GAS5 in prostate cancer ZNF775 inhibits MCF-7 breast cancer cell migration by downregulating Wnt5a Niosomes containing enciprazine hydrochloride have been shown to efficiently inhibit the proliferation and induce apoptosis in colorectal cancer cells Navigating the interplay between BCL-2 family proteins, apoptosis, and autophagy in colorectal cancer PD-L1 and PD-1 in immune regulation and their implications in blood cancers
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1